Literature DB >> 18175273

Positron emission tomography for use in microdosing studies.

Claudia Christina Wagner1, Markus Müller, Graham Lappin, Oliver Langer.   

Abstract

Positron emission tomography (PET) imaging using microdoses of radiolabeled drug tracers is gaining increasing acceptance in modern clinical drug development. This approach is unique in that it allows for direct quantitative assessment of drug concentrations in the tissues targeted for treatment, thereby bridging the gap between pharmacokinetics and pharmacodynamics. Current applications of PET in anticancer, anti-infective and central nervous system drug research are reviewed herein. Situated at the interface of preclinical and clinical drug testing, PET microdosing is a powerful and highly innovative tool for pharmaceutical development.

Mesh：

Substances：

Year:  2008        PMID： 18175273

Source DB:  PubMed          Journal:  Curr Opin Drug Discov Devel        ISSN： 1367-6733


  9 in total

1.  Pgp-mediated interaction between (R)-[11C]verapamil and tariquidar at the human blood-brain barrier: a comparison with rat data.

Authors:  M Bauer; M Zeitlinger; R Karch; P Matzneller; J Stanek; W Jäger; M Böhmdorfer; W Wadsak; M Mitterhauser; J P Bankstahl; W Löscher; M Koepp; C Kuntner; M Müller; Oliver Langer
Journal:  Clin Pharmacol Ther       Date:  2011-12-14       Impact factor: 6.875

Review 2.  Phase 0/microdosing approaches: time for mainstream application in drug development?

Authors:  Tal Burt; Graeme Young; Wooin Lee; Hiroyuki Kusuhara; Oliver Langer; Malcolm Rowland; Yuichi Sugiyama
Journal:  Nat Rev Drug Discov       Date:  2020-09-08       Impact factor: 84.694

Review 3.  Microdosing and drug development: past, present and future.

Authors:  Graham Lappin; Robert Noveck; Tal Burt
Journal:  Expert Opin Drug Metab Toxicol       Date:  2013-04-04       Impact factor: 4.481

4.  Development of new deoxycytidine kinase inhibitors and noninvasive in vivo evaluation using positron emission tomography.

Authors:  Jennifer M Murphy; Amanda L Armijo; Julian Nomme; Chi Hang Lee; Quentin A Smith; Zheng Li; Dean O Campbell; Hsiang-I Liao; David A Nathanson; Wayne R Austin; Jason T Lee; Ryan Darvish; Liu Wei; Jue Wang; Ying Su; Robert Damoiseaux; Saman Sadeghi; Michael E Phelps; Harvey R Herschman; Johannes Czernin; Anastassia N Alexandrova; Michael E Jung; Arnon Lavie; Caius G Radu
Journal:  J Med Chem       Date:  2013-08-15       Impact factor: 7.446

5.  A combined accelerator mass spectrometry-positron emission tomography human microdose study with 14C- and 11C-labelled verapamil.

Authors:  Claudia C Wagner; Marie Simpson; Markus Zeitlinger; Martin Bauer; Rudolf Karch; Aiman Abrahim; Thomas Feurstein; Matthias Schütz; Kurt Kletter; Markus Müller; Graham Lappin; Oliver Langer
Journal:  Clin Pharmacokinet       Date:  2011-02       Impact factor: 6.447

Review 6.  Approaches using molecular imaging technology -- use of PET in clinical microdose studies.

Authors:  Claudia C Wagner; Oliver Langer
Journal:  Adv Drug Deliv Rev       Date:  2010-09-29       Impact factor: 15.470

7.  In Vivo Tissue Pharmacokinetics of Carbon-11-Labeled Clozapine in Healthy Volunteers: A Positron Emission Tomography Study.

Authors:  H S Park; E Kim; B S Moon; N H Lim; B C Lee; S E Kim
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2015-04-24

8.  Tissue pharmacokinetics of DHP107, a novel lipid-based oral formulation of paclitaxel, in mice and patients by positron emission tomography.

Authors:  Byung Seok Moon; Hyun Soo Park; Jung Sunwoo; In-Hyun Lee; Anhye Kim; Seol Ju Moon; Heechan Lee; Min Hee Son; Su Bin Kim; Sun Mi Park; Sang-Keun Woo; Jun-Hee Jang; Bom Sahn Kim; Jee Hyun Kim; Sang Eun Kim; Howard Lee
Journal:  Clin Transl Sci       Date:  2021-06-04       Impact factor: 4.689

Review 9.  Strategic, feasibility, economic, and cultural aspects of phase 0 approaches: Is it time to change the drug development process in order to increase productivity?

Authors:  Tal Burt; Ad F Roffel; Oliver Langer; Kirsten Anderson; Joseph DiMasi
Journal:  Clin Transl Sci       Date:  2022-04-21       Impact factor: 4.438
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.